These atomic-level maps of TRPM4 facilitates ongoing development of specific TRPM4 inhibitors that can act through selectively obstructing its Ca2+-activation binding site or to inhibit TRPM4 via NBD binding, providing expanded avenues to therapeutically target TRPM4 in cancers. Here, TRPM4 is linked to cancer.